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Background: Clinical evidence on patient-reported outcome measures (PROMS) in breast reconstruc-
tion is lacking. The aim of this study was to evaluate PROMs in implant-assisted latissimus dorsi (LDI)
or tissue-only autologous latissimus dorsi (ALD) flap reconstruction in relation to complications and
adjuvant treatments.
Methods: This was a prospective cohort study involving six UK centres. Eligible patients had primary
early-stage breast cancer. The European Organization for Research and Treatment of Cancer quality-
of-life questionnaire (QLQ)-C30 and QLQ-BR23, Functional Assessment of Cancer Therapy – Breast
Cancer scale (FACT-B), Body Image Scale, and Hospital Anxiety and Depression Scale were completed
before operation and at 3, 6 and 12 months after surgery.
Results: A total of 182 patients (82 LDI and 100 ALD) were recruited between 2007 and 2010 with
symptomatic (59·9 per cent) or screen-detected (39·6 per cent) cancers. Some 64·3 per cent had lymph
node-negative disease; 30 per cent of the LDI group had radiotherapy, compared with 53·0 per cent
in the ALD group (P = 0·004). Early complications up to 3 months after surgery were reported in
66 and 51·0 per cent of patients in the LDI and ALD groups respectively (P = 0·062) and long-term
complications (4–12 months) in 48 and 45·0 per cent (P = 0·845). Role functioning and pain (P = 0·002
for both) were adversely affected in the ALD group compared with results in the LDI group, with
no significant effects of radiotherapy on any health-related quality of life (HRQL). Chemotherapy and
early complications adversely affected HRQL, which improved between 3 and 12 months after surgery
(P < 0·010 for all).
Conclusion: There is evidence of similar HRQL between types of latissimus dorsi breast reconstruction
for up to a year after surgery. There appear to be no overarching effects for radiotherapy aftermastectomy
on the specificHRQL domains studied in the short term. The identification of variables that affect HRQL
is important, including their integration into the analysis of PROMs.
*Members of the Prospective Trial Management Group are co-authors of this study and can found under the heading
Collaborators
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Introduction
Earlier detection and improved treatments for breast
cancer have yielded long-term survival rates of more than
80 per cent following initial diagnosis1. This has increased
the focus on the impact of surgical and other treatments on
health-related quality of life (HRQL)2.Up to 40 per cent of
women diagnosed annually with breast cancer in the UK
undergo mastectomy3, which affects their quality of life
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in terms of psychosocial, physical, aesthetic, body image
and sexual issues4,5. Indeed, more than half of women
experience general health problems according to the UK
National Mastectomy and Breast Reconstruction Audit3.
Whatever the potential psychological beneﬁts, the UK
National Institute for Health and Clinical Excellence
(NICE) recommends that reconstruction be offered as
an immediate procedure to all women who have had
a mastectomy6. The UK breast reconstruction audit
revealed that 21 per cent of women underwent immediate
breast reconstruction between 2008 and 2009, compared
with 11 per cent in 2005–20063,6. Although a range of
reconstructive surgery is practised, from simple subpectoral
implant insertion to complex free ﬂaps, a latissimus
dorsi (LD)-based ﬂap is one of the most widely offered
procedures in the UK3. The UK breast reconstruction
audit found that pedicled ﬂaps, whether autologous or
implant-assisted, constituted almost half of all immediate
and delayed breast reconstructions, compared with free
microvascular ﬂaps3. The types of LD technique are well
established; autologous breast reconstruction performed
as an extended LD dissection is routine in many
units3,7.
Increasingly, decisions on adjuvant therapies inﬂuence
recommendations for either immediate or delayed breast
reconstruction7. Postmastectomy radiotherapy (PMRT)
may confer a survival beneﬁt when combined with
systemic adjuvant therapies8; approximately 40 per cent
of women in the UK receive PMRT3. Broadened
indications for PMRT are modifying the practice of breast
reconstruction surgery, in terms of both timing and type9.
Complication rates following irradiation of implant-based
reconstructions are high, with severe capsular contracture
rates of 28 per cent at 4 years7. Many surgeons are
reluctant to recommend immediate implant-assisted LD
reconstruction in this setting and favour either a delayed
or a staged procedure7,9. By contrast, exclusively tissue-
based autologous breast reconstruction is more tolerant
of radiotherapy. There were no signiﬁcant differences in
patient self-reported cosmetic outcomes or body image
between types of LD breast reconstruction, regardless of
PMRT, at a median follow-up of 3 years7.
Clinical trials should incorporate outcomes from the
perspective of patients: patient-reported outcomemeasures
(PROMs)10. Evidence should include the impact of an
intervention on the patient in terms of HRQL, to assess
net beneﬁts fully5. Two systematic reviews on breast
reconstruction and HRQL revealed the majority of studies
to be ﬂawed methodologically, with no data evaluating the
effects of LD breast reconstruction on HRQL4,11.
Randomized clinical trials are controversial in the
ﬁeld of breast reconstruction. Prospective cohort studies
potentially can recruit a larger and more representative
sample of patients4,11,12. The present study was a pilot
phase to a planned randomized controlled trial and was
designed as hypothesis-generating, with no a priori primary
outcome deﬁned. A prospective longitudinal study was
conducted in several centres to evaluate whether any
differences in HRQL could be demonstrated in terms
of the extent of donor-site tissue dissection following
immediate LD breast reconstruction with, and without
adjuvant chemotherapy and/or PMRT.
Methods
A prospective longitudinal cohort study was carried
out (National Research Ethics Committee Wiltshire:
05/Q2008/14 approval) in six UK centres (Bristol,
Cambridge, Glasgow, Hull, Swindon and York) with
patients recruited between January 2007 and May 2010.
Women with pathologically conﬁrmed stage 0–II breast
cancer13, including ductal carcinoma in situ (DCIS), and
women with bilateral disease were included in the study.
Womenwith a previous breast cancerwere excluded.Other
contraindications to immediate breast reconstruction were
applicable, such as surgical or medical co-morbidity, or
metastatic disease.
Eligible women gave written informed consent after
biopsy conﬁrmation of breast cancer. Participants were
assessed before surgery for the likelihood of PMRT
according to local policy using information from breast
magnetic resonance imaging (MRI) and/or sentinel lymph
node biopsy14,15. MRI was used to determine tumour
size, multicentricity, or proximity to pectoral muscle and
skin. Women eligible for neoadjuvant chemotherapy, but
who ultimately required mastectomy, were included. In
accordance with the UK NICE guidelines, all women
had fully informed discussions regarding the range
of reconstructive options, likelihood of PMRT, co-
morbidities and patient preferences16. Informed consent
was obtained on the part of all healthcare professionals,
and was recommended according to national guidelines.
The process regarding the surgical choice by the patient
or the healthcare professionals across the six centres was
beyond the scope of the study. HRQL questionnaire
packs were handed directly to patients at the second
preoperative visit (baseline), and subsequently posted with
a self-addressed freepost envelope at 3, 6 and 12 months
after surgery. Recurrent (local or distant) disease did not
exclude questionnaire administration, except in the context
of conﬁrmed cerebral metastases.
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Primary endpoints
HRQL was assessed using validated self-reported patient
measures to evaluate the impact of breast cancer and its
treatment5,17,18. The European Organization for Research
and Treatment of Cancer (EORTC) generic quality-
of-life questionnaire QLQ-C30 was used19, comprising
functional and symptom subscales. The EORTC breast
cancer module (QLQ-BR23) was used to evaluate breast
and arm symptoms19, and the ten-item Body Image Scale
(BIS)20 was employed as a measure of body image.
The Hospital Anxiety and Depression Scale (HADS),
consisting of two subscales to distinguish anxiety and
depression, was used to evaluate the need for psychological
referral21. Finally, the Functional Assessment of Cancer
Therapy – Breast Cancer scale (FACT-B) quality-of-life
questionnaire was used, which is designed for women with
breast cancer and includes subscales assessing physical,
social, emotional and functional wellbeing22. These
PROMs were used in the absence of any other validated
breast reconstruction-speciﬁc questionnaires available at
the commencement of the study4,11.
Secondary endpoints
Patient response rates for questionnaire completion were
documented at all time points18. Adverse events and
complications were collected as per protocol on clini-
cal record forms, and stratiﬁed by severity and timing
after surgery using the classiﬁcation system described
by Dindo–Clavien23. Locoregional recurrence and dis-
tant metastatic disease were deﬁned using established
criteria24.
Patient characteristics
Explanatory variables used in the study included age
at diagnosis, menopausal status, mode of breast cancer
detection, tumour characteristics, co-morbidities, treat-
ments received (including surgery, chemotherapy, hor-
mone therapy and radiotherapy) and sociodemographic
factors2,5,24.
Follow-up
Clinical follow-up was scheduled at 1 and 2 weeks after
surgery, then at 3, 6 and 12 months from the date of
operation. Early (up to and including 3 months) and long-
term (from 4 to 12 months) postsurgical complications
were documented, as well as any subsequent surgical
interventions. Complications were graded as minor (level
1, no speciﬁc intervention), moderate (level 2, requirement
for antibiotics or blood transfusion) or severe (level 3,
indication for surgery – local or general anaesthesia)23.
Statistical analysis
This was primarily a hypothesis-generating study, so the
sample size was determined on the basis of obtaining sufﬁ-
cient numbers of women in the main treatment groups of
interest for statistical analysis, rather than to test a speciﬁc
a priori hypothesis. The four treatment groups of interest
(with the expected proportions in each group) were LD
implant without radiotherapy (60 per cent), LD implant
with radiotherapy (10 per cent), extended autologous LD
without radiotherapy (20 per cent) and extended autolo-
gous LD with radiotherapy (10 per cent)3,7. A target of at
least 150 women for the total study size was set, with the
aim of providing a minimum of 15 patients within each
category.
Demographic and clinical data were compared between
the surgical groups using the χ2 test, χ2 test for trend
or Fisher’s exact test where appropriate, for categorical
variables. Quantitative data were summarized using the
mean and standard deviation (s.d.) or the median and
interquartile range (i.q.r.) where distributions were skewed,
and compared between surgical groups using the t test
or Mann–Whitney U test respectively. Rates of speciﬁc
types of early and long-term complications were not
compared formally between surgical groups, as numbers
in some categories were small. HRQL subscales were
summarized using the median (i.q.r.) as distributions
were skewed. The 3- and 12-month time points were
selected for graphical presentation of the HRQL subscales
as these were considered to represent short- and long-
term outcomes for the study. Longitudinal analysis was
done by ﬁtting a separate generalized estimating equations
model for each HRQL subscale, which included all
of the following potential predictors: type of surgery,
radiotherapy, chemotherapy, early (3 months or less) and
long-term (4–12 months) complications, age at operation,
time point (3, 6 or 12 months) and baseline (before surgery)
HRQL score. To take account of the many signiﬁcance
tests performed, a more conservative cut-off was taken to
indicate statistical signiﬁcance (P ≤ 0·010). The statistical
program SPSS version 19 (IBM, Armonk, New York,
USA) was used for statistical analysis.
Results
Of the 236 women assessed for eligibility, 182 were
recruited; 82 (45·1 per cent) had implant-assisted latissimus
dorsi (LDI) and 100 (54·9 per cent) had autologous
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Recruited into prospective observational
cohort n = 182
Baseline questionnaire
    completed n = 19
Questionnaire not
    returned n = 6
Baseline questionnaire
     completed n = 47
Questionnaire not
     returned n = 10
Baseline questionnaire
    completed n = 45
Questionnaire not
    returned n = 1
Patient not followed
    up n = 1
Baseline questionnaire
    completed n = 46
Questionnaire not
     returned n = 7
6-month questionnaire
    completed n = 23
Questionnaire not sent
    out n = 2
6-month questionnaire
    completed n = 52
Questionnaire not
    returned n = 2
Questionnaire not sent
    out n = 3
6-month questionnaire
    completed n = 39
Questionnaire not
     returned n = 1
Questionnaire not sent
     out n = 6
Patients not followed
     up n = 1
6-month questionnaire
   completed n = 43
Questionnaire not
    returned n = 4
Questionnaire not sent
    out n = 6
12-month
    questionnaire
    completed n = 20
Questionnaire not
    returned n = 5
12-month
    questionnaire
    completed n = 52
Questionnaire not
    returned n = 4
Questionnaire not sent
    out n = 1
12-month
    questionnaire
    completed n = 46
Patient not followed
    up n = 1
12-month
    questionnaire
    completed n = 51
Questionnaire not
    returned n = 2
3-month questionnaire
    completed n = 21
Questionnaire not sent
     out n = 4
3-month questionnaire
    completed n = 47
Questionnaire not
    returned n = 2
Questionnaire not sent
    out n = 8
3-month questionnaire
   completed n = 36
Questionnaire not sent
    out n = 10
Patient not followed
    up n = 1
3-month questionnaire
   completed n = 40
Questionnaire not
     returned n = 4
Questionnaire not sent
     out n = 9
Assessed for eligibility
n = 236 Patients excluded n = 54
Prophylactic n = 6
Declined n = 18
Withdrawn n = 2
Recurrence n = 4
Died n = 4
Delayed reconstruction n = 7
Subpectoral surgery only n = 1
No reconstruction n = 1
No surgery n = 1
Implant only n = 1
Surgery at peripheral hospital n = 1
Recruited in error n = 1
ALD surgery and implant n = 7
Recruited to ALD
n = 100
Recruited to LDI
n = 82
No radiotherapy n = 47Radiotherapy n = 25No radiotherapy n = 57 Radiotherapy n = 53
Fig. 1 Progress of participants through the study. The numbers of questionnaires not sent to patients and patients not followed up
relate to administrative error and do not reﬂect recurrent disease. Questionnaires unreturned by patients are in keeping with
protocol-deﬁned reminder letters and contact with patients. ALD, autologous latissimus dorsi breast reconstruction; LDI,
implant-assisted latissimus dorsi breast reconstruction
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Table 1 Comparison of baseline demographic and clinical characteristics in women having implant-assisted or extended latissimus dorsi
breast reconstruction
LDI (n = 82) ALD (n = 100) P§
Age (years)* 51·1(9·5) 49·4(8·3) 0·187¶
Body mass index (kg/m2)* 25·2(4·0) 27·4(4·8) 0·001¶
Highest educational level No formal qualifications/vocational
qualifications only
8 (10) 19 (19·0) 0·023#
Ordinary level/GCSE 29 (35) 36 (36·0)
Advanced level 11 (13) 17 (17·0)
University degree/postgraduate 31 (38) 22 (22·0)
Unknown 3 (4) 6 (6·0)
Employed No 30 (37) 22 (22·0) 0·050
Yes 52 (63) 77 (77·0)
Unknown 0 (0) 1 (1·0)
Other medical illnesses No 69 (84) 91 (91·0) 0·237
Yes 13 (16) 9 (9·0)
Previous breast or axillary None 44 (54) 58 (58·0) 0·401
surgery Wide local excision 25 (30) 24 (24·0)
Other (including SLN-assisted sample, SLN) 6 (7) 12 (12·0)
Unknown 7 (9) 6 (6·0)
Neoadjuvant chemotherapy No 79 (96) 83 (83·0) 0·009
Yes 3 (4) 17 (17·0)
Reason for surgery Screen-detected 37 (45) 35 (35·0) 0·191
Symptomatic 44 (54) 65 (65·0)
Unknown 1 (1) 0 (0)
Pattern of mastectomy NAC excision 73 (89) 89 (89·0) 0·960††
Nipple-sparing 3 (4) 1 (1·0)
Reduction mammoplasty 3 (4) 7 (7·0)
Standard mastectomy 1 (1) 2 (2·0)
Unknown 2 (2) 1 (1·0)
Dry weight of mastectomy 432 (261–573, 480 (349–642, 0·047**
specimen (g)† 90–1860) 134–1797)
Type of axillary surgery None 7 (9) 6 (6·0) < 0·001
Level 1 axillary clearance 16 (20) 2 (2·0)
Level 2/3 axillary clearance 31 (38) 56 (56·0)
Axillary lymph node sample 16 (20) 14 (14·0)
SLN-assisted sample 12 (15) 21 (21·0)
Unknown 0 (0) 1 (1·0)
Closure of back wound Standard two-layer 25 (30) 29 (29·0) 0·026
Quilting 37 (45) 59 (59·0)
Other‡ 20 (24) 10 (10·0)
Unknown 0 (0) 2 (2·0)
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.), and †values are median (interquartile range, range) for 68 and 85
patients with data on dry weight of mastectomy specimen in implant-assisted latissimus dorsi breast reconstruction (LDI) and autologous latissimus dorsi
breast reconstruction (ALD) groups respectively. ‡For example ﬁbrin sealant or triamcinolone. GCSE, General Certiﬁcate of Secondary Education;
NAC, nipple–areolar complex; SLN, sentinel lymph node. §χ2 test, except ¶t test, #χ2 test for trend and **Mann–Whitney U test; ††NAC excision
versus all others (unknown categories were excluded from signiﬁcance tests).
latissimus dorsi (ALD) breast reconstruction procedures
(Fig. 1). Sociodemographic characteristics were similar
between the surgical groups (Table 1), with a mean
patient age of 50 years. A signiﬁcantly higher mean body
mass index was evident among women in the ALD
compared with the LDI group (27·4 versus 25·2 kg/m2;
P = 0·001). Clinical characteristics were similar between
the surgical groups for many of the assessed criteria,
such as menopausal, marital, educational, employment
and current smoking status, including other medical
illnesses (Table 1; data not shown). Some 87·9 per cent of
women had no signiﬁcant co-morbidities; 26·9 per cent
of women had undergone a recent therapeutic wide
local excision, which subsequently required completion
mastectomy to achieve surgical margin clearance. Baseline
HRQL data for this group were comparable to those in
patients undergoing mastectomy as the ﬁrst procedure,
although role functioning and arm symptoms were notably
worse when mastectomy followed previous wide local
excision (data not shown). Similar distributions of need
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Table 2 Comparison of pathology and adjuvant treatment in women having implant-assisted or extended latissimus dorsi breast
reconstruction
LDI (n = 82) ALD (n = 100) P¶
Pathology† Invasive breast cancer only 33 (40) 29 (29·0) 0·020
DCIS only 22 (27) 17 (17·0)
Invasive + DCIS 27 (33) 53 (53·0)
Unknown 0 (0) 1 (1·0)
Tumour size (mm)* ‡ Invasive 19 (12–22, 2–70) 20 (13–29, 2–100) 0·152#
DCIS 32 (15–50, 1–85) 31·5 (17–45, 1–120) 0·924#
Grade (invasive) 1 15 (25) 10 (12) 0·111**
2 29 (48) 40 (49)
3 15 (25) 29 (35)
Unknown 1 (2) 3 (4)
Multifocal No 37 (45) 51 (51·0) 0·522
Yes 45 (55) 49 (49·0)
Lymphovascular invasion No 60 (73) 55 (55·0) 0·019
Yes 19 (23) 40 (40·0)
Unknown 3 (4) 5 (5·0)
Margin positivity (<1 mm)§ Invasive 13 of 59 (22) 4 of 79 (5) 0·006
DCIS 8 of 47 (17) 13 of 66 (20) 0·908
Lymph node status* No. of nodes removed 8 (5–12, 0–22) 9 (5–14, 0–36) 0·297#
No. of involved nodes 0 (0–1, 0–14) 0 (0–2, 0–26) 0·016#
Lymph node positivity Yes 22 (27) 43 (43·0) 0·035
No 60 (73) 57 (57·0)
Postmastectomy chemotherapy No 45 (55) 51 (51·0) 0·710
Yes 37 (45) 49 (49·0)
Herceptin No 27 (33) 26 (26·0) 0·541
Yes 7 (9) 11 (11·0)
Unknown 2 (2) 1 (1·0)
NA (HER2 negative) 46 (56) 62 (62·0)
Hormone therapy None 10 (12) 14 (14·0) 0·283
Tamoxifen 41 (50) 39 (39·0)
Aromatase inhibitor 15 (18) 26 (26·0)
Unknown 2 (2) 1 (1·0)
NA (oestrogen receptor-negative) 14 (17) 20 (20·0)
Postmastectomy radiotherapy No 57 (70) 47 (47·0) 0·004
Yes 25 (30) 53 (53·0)
Values in parentheses are percentages unless indicated otherwise; *values are median (interquartile range, range). †Thus there were 60 cases of invasive
cancer in the implant-assisted latissimus dorsi breast reconstruction (LDI) group and 82 cases in the autologous latissimus dorsi breast reconstruction
(ALD) group, and 49 and 70 cases of ductal carcinoma in situ (DCIS) in the LDI and ALD groups respectively. ‡Tumour size was unknown for one
invasive case in the ALD group and one DCIS case in the LDI group. §Margin status was unknown for one and three cases of invasive cancer, and for two
and four cases of DCIS in the LDI and ALD groups respectively. NA, not applicable; HER2, human epidermal growth factor receptor 2. ¶χ2 test, except
#Mann–Whitney U test, **χ2 test for trend (unknown and NA categories were excluded from signiﬁcance tests).
for completion mastectomy between the surgical groups
precluded any formal correction for this variable. Patients
in the ALD group were more likely to have received
neoadjuvant chemotherapy than those in the LDI group
(17·0 versus 4 per cent respectively; P = 0·009).
Few women were current users of hormone replacement
therapy or bisphosphonates (data not shown). The indica-
tions for mastectomy were similar in the two groups and
a contralateral reduction mammoplasty was seldom neces-
sary in either group (4 per cent for LDI versus 7 per cent
for ALD). Axillary lymph node dissection was done more
often in the ALD compared with the LDI group (56·0
versus 38 per cent respectively; P < 0·001), in accordance
with histopathology ﬁndings (Tables 1 and 2). Established
and newer interventions were used to reduce donor-site
seromas24.
Histopathology, treatments and complications
Patients included those with invasive carcinoma (34·1
per cent), extensive DCIS (21·4 per cent) and combined
pathology (44·0 per cent) (Table 2). The median tumour
size was 20 mm for the invasive component. More
aggressive tumour characteristics were evident in the
ALD group, with higher-grade tumours, more frequent
lymphovascular invasion and higher rates of lymph node
positivity, although the differences were not statistically
signiﬁcant. The signiﬁcantly greater margin positivity
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rate of 22 per cent for invasive disease in the LDI
group, compared with 5 per cent in the ALD group, is
largely inexplicable and would necessitate consideration of
PMRT14,15. There were no differences between the groups
for hormone receptors and human epidermal growth factor
receptor (HER2) (data not shown). Adjuvant chemother-
apy was administered to 47·3 per cent of women, and was
similar in both groups, but PMRT was more common in
women undergoing ALD (53·0 per cent versus 30 per cent
for LDI; P = 0·004) (Table 2). There were no differences
between groups for adjuvant endocrine or herceptin treat-
ment (data not shown). The numbers of patients with
local and systemic recurrence were comparable between
the groups, and were limited to a total of two and three
patients respectively, with no deaths within 12 months.
Patients in the LDI and ALDgroups had similar levels of
early complications up to 3 months after surgery (66 versus
51·0 per cent respectively), and of long-term complications
from 4 to 12 months (48 versus 45·0 per cent respectively)
(Table 3).
Table 3 Comparison of early and late complications after surgery in women having implant-assisted or extended latissimus dorsi breast
reconstruction
LDI (n = 82) ALD (n = 100) P§
Early complications (0–3 months)
Any early complication None 28 (34) 49 (49·0) 0·062
Yes 54 (66) 51 (51·0)
Highest level† Minor 17 of 54 (31) 21 of 51 (41) 0·116¶
Moderate 12 of 54 (22) 15 of 51 (29)
Severe 25 of 54 (46) 15 of 51 (29)
Breast Infection 8 of 54 (15) 4 of 51 (8)
Fat necrosis 7 of 54 (13) 8 of 51 (16)
Skin necrosis 23 of 54 (43) 11 of 51 (22)
Haematoma 2 of 54 (4) 2 of 51 (4)
Implant infection or displacement 6 of 54 (11) NA
Other (nipple loss, dehiscence, lymphoedema of
breast or arm)
5 of 54 (9) 2 of 51 (4)
Back Dehiscence 9 of 54 (17) 3 of 51 (6)
Infection 5 of 54 (9) 8 of 51 (16)
Seroma (>5 aspirations) 22 of 54 (41) 25 of 51 (49)
Skin necrosis 17 of 54 (31) 21 of 51 (41)
Other (loculated seroma, back pain, haematoma) 9 of 54 (17) 10 of 51 (20)
Reoperation No 32 (39) 35 (35·0) 0·685
Yes 50 (61) 65 (65·0)
Reason for reoperation Complications 24 of 50 (48) 20 of 65 (31)
To achieve symmetry/improve cosmetic appearance‡ 16 of 50 (32) 22 of 65 (34)
Nipple reconstruction 28 of 50 (56) 49 of 65 (75)
Other (including prophylactic mastectomy) 7 of 50 (14) 2 of 65 (3)
Long-term complications (4–12 months)
Any long-term complication None 43 (52) 55 (55·0) 0·845
Yes 39 (48) 45 (45·0)
Highest level† Minor 14 of 39 (36) 27 of 45 (60) 0·042¶
Moderate 6 of 39 (15) 4 of 45 (9)
Severe 19 of 39 (49) 14 of 45 (31)
Complications Capsular contracture 6 of 39 (15) 0 of 45 (0)
Lymphoedema, breast 4 of 39 (10) 7 of 45 (16)
Restriction of arm/shoulder movement 6 of 39 (15) 5 of 45 (11)
Dog ear of any wound 8 of 39 (21) 16 of 45 (36)
Implant complications 5 of 39 (13) NA
Back symptoms (e.g. stiffness, tightness, discomfort) 6 of 39 (15) 13 of 45 (29)
Other complications (including lymphoedema of arm,
loss of breast volume, asymmetry)
17 of 39 (44) 14 of 45 (31)
Values in parentheses are percentages. †Dindo–Clavien classiﬁcation of surgical complications23: minor (level 1), no pharmacological treatments as
deviation from normal postoperative course; moderate (level 2), pharmacological treatments for complications (antibiotics, blood transfusions); severe
(level 3), surgical intervention, either local or general anaesthetic. ‡Excluding nipple reconstruction. LDI, implant-assisted latissimus dorsi breast
reconstruction; ALD, autologous latissimus dorsi breast reconstruction; NA, not applicable. §χ2 test, except ¶χ2 test for trend (unknown categories were
excluded from signiﬁcance tests).
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Patient-reported outcome measures and
health-related quality of life
Patient response rates for questionnaire completion were
86·3 per cent at baseline and 92·9 per cent at 12 months,
with similar rates between the treatment groups (Fig. 1).
Patterns of distributions of HRQL outcomes were similar
between the surgery groups over time, with many of
the outcomes from EORTC QLQ-C30 and QLQ-BR23
worsening from baseline to 3 months, and subsequently
improving by 12 months (Fig. 2).
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Fig. 2 Distribution of health-related quality-of-life (QoL) outcomes up to 1 year after implant-assisted latissimus dorsi (LDI) or
autologous latissimus dorsi (ALD) breast reconstruction. a Median (interquartile range, i.q.r.) score for global QoL, and for role and
social functioning domains on the European Organization for Research and Treatment of Cancer (EORTC) cancer generic
quality-of-life questionnaire (QLQ-C30; range 0–100). b Median (i.q.r.) score for fatigue, pain and breast symptoms on the EORTC
QLQ-C30 and the breast cancer module QLQ-BR23 (range 0–100). c Median (i.q.r.) total score on the Functional Assessment of
Cancer Therapy – Breast Cancer scale (FACT-B; range 0–144). d Anxiety and e depression on the Hospital Anxiety and Depression
Scale (HADS; range 0–21: 0–7, normal; 8–10, borderline; 11 or more, case)
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Table 4 Results of generalized estimating equation models investigating clinical and demographic predictors of health-related quality of
life 3–12 months after breast reconstruction surgery
Predictor of worse HRQL (P value)
HRQL subscale
Surgery (ALD
versus LDI) Radiotherapy Chemotherapy
Early
complications*
Long-term
complications*
Younger
age
Less time
since surgery
EORTC QLQ-C30 and QLQ-BR23
Global quality of life 0·195 0·457 < 0·001 <0·001 0·158 0·302 <0·001
Role functioning 0·002 0·330 0·026 <0·001 0·684 0·278 <0·001
Social functioning 0·823 0·563 0·001 0·001 0·355 0·020 <0·001
Fatigue 0·285 0·311 0·006 <0·001 0·814 0·326 <0·001
Pain 0·002 0·687 0·091 0·001 > 0·99 0·671 <0·001
Breast symptoms 0·800 0·487 0·929 <0·001 0·014 0·147 0·009
Arm symptoms 0·103 0·216 0·360 0·341 0·074 0·969 0·091
Body Image Scale 0·491 0·983 0·891 0·079 < 0·001 0·021 0·079
HADS
Anxiety 0·279 0·373 0·183 0·083 0·367 0·012 0·587
Depression 0·236 0·572 0·035 <0·001 0·826 0·368 0·002
FACT-B
Physical wellbeing 0·076 0·033 0·060 0·011 0·877 0·330 <0·001
Social wellbeing 0·290 0·560 0·438 0·374 0·558 0·360 0·337
Emotional wellbeing 0·870 0·018 0·474 0·158 0·227 0·209 0·040
Functional wellbeing 0·485 0·574 < 0·001 <0·001 0·844 0·619 <0·001
Breast cancer subscale 0·813 0·333 0·002 0·574 0·090 0·480 <0·001
FACT-B total score 0·519 0·215 < 0·001 0·011 0·468 0·493 <0·001
*Early (0–3 months) and long-term (4–12 months) complications graded by the Dindo–Clavien classiﬁcation23 as none, minor, moderate or severe.
HRQL, health-related quality of life; ALD, autologous latissimus dorsi breast reconstruction; LDI, implant-assisted latissimus dorsi breast
reconstruction. EORTC QLQ, European Organization for the Research and Treatment of Cancer quality-of-life questionnaire; HADS, Hospital
Anxiety and Depression Scale; FACT-B, Functional Assessment of Cancer Therapy– Breast Cancer scale. Separate models were ﬁtted for each HRQL
subscale including all predictors listed in the table and the baseline value of the HRQL subscale. P < 0·010 indicates that the predictor was signiﬁcantly
associated with worse levels of the HRQL subscale.
Among theHRQLmeasures, only two domains from the
EORTC QLQ-C30 (role functioning and pain) were sig-
niﬁcantly worsened after ALD compared with LDI recon-
struction (P = 0·002 for both).HRQLwas not signiﬁcantly
different according to PMRT or age. Chemotherapy
(adjuvant and neoadjuvant) signiﬁcantly impaired global
quality of life (P < 0·001), social functioning (P = 0·001)
and fatigue (P = 0·006), as well as functional wellbeing
(P < 0·001) and the breast cancer subscale (P = 0·002) and
total score (P < 0·001) for FACT-B (Table 4).
Early complications had statistically signiﬁcant adverse
effects on many of the EORTC and some FACT-B
subscales, with increased levels of depression according
to HADS. Longer-term complications appeared to have
a lesser impact, with a signiﬁcant adverse effect only on
body image (P < 0·001). Signiﬁcant improvements from
3 to 12 months were noted for global quality of life, role
and social functioning, fatigue, pain (P < 0·001 for all),
breast symptoms (P = 0·009) and depression (P = 0·002),
as well as physical and functional wellbeing, the breast
cancer subscale and the total score for FACT-B (P < 0·001
for all) (Table 4). Baseline/preoperative HRQL scores
were statistically signiﬁcant predictors of scores from 3
to 12 months after surgery for many of the domains
investigated, and consequently were adjusted for in the
regression models.
Discussion
These results conﬁrm the independent adverse effects of
early surgical complications onmost aspects ofHRQLover
the ﬁrst 12 months after surgery, which are compounded by
chemotherapy. The PROMs used here did not distinguish
any signiﬁcant overall differences between the types of
LD ﬂap breast reconstruction with, and without PMRT.
Only two of all the selected HRQL domains, pain and
role functioning, were signiﬁcantly worse after ALD
ﬂap reconstruction. This may be explained by poorly
practised preventive measures regarding pain control and
physiotherapy referral, as reported in the UK breast
reconstruction audit3. These ﬁndings need to be explored
further, with longer-term follow-up, in a formal clinical
trial setting.
PMRT did not affect any aspect of women’s quality of
life in the investigated domains. The need to individualize
options for immediate reconstruction when PMRT is
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anticipated is predicated on better radiation tolerability
by autologous ﬂaps7,25. No differences in PROMs were
found in a single randomized trial evaluating delayed
autologous ﬂaps following PMRT in a small group
of 28 patients26. Fewer than a quarter (n = 6) of
the studies included in systematic reviews contained
patients who had received PMRT, of which ﬁve were
retrospective studies with limited patient numbers4,11.
Studies employing single cross-sectional analysis have
shown ‘excellent’ or ‘good’ PROMs following PMRT after
either immediate ALD breast reconstruction or autologous
microvascular free ﬂaps7,25. Importantly, these ﬁndings
suggest there was no independent effect of PMRT on
PROMs using a repeated-measures analysis, conﬁrming
a previous related analysis7. Such evidence represents a
major shift in treatment recommendations and contrasts
with ﬁndings from historical studies on irradiation of
immediate free microvascular ﬂaps9. The present study
examined the effects of PMRT on HRQL after LDI breast
reconstruction on an intention-to-treat basis and found
no demonstrable effects on HRQL. However, the practice
of LDI breast reconstruction would still not currently
be recommended when expectation of PMRT is high7,9.
None of the four prospective studies in two systematic
reviews evaluated the number of women who received
chemotherapy, and did not account for its potential effects
on HRQL after breast reconstruction. Moreover, none
of these studies analysed HRQL results in the context
of multivariable regression analyses that incorporated
adjuvant treatments4,11.
Women choosing immediate breast reconstruction have
sociodemographic and clinical characteristics that may
inﬂuence HRQL outcomes, including patient preferences
and the complexity of patient choice27. The groups
studied here were comparable sociodemographically, thus
negating any potential differential effects on HRQL.
Inherent biases on the part of patients, surgeons and
healthcare professionals are inevitable confounding factors,
including selection bias of ALD for those anticipated
to require PMRT7,9. One of the strengths of this
study is the integration of surgical complications into
analyses of surgical factors on PROMs4,11. Higher level
3 complications at 3 months in this study compared
with the National Mastectomy and Breast Reconstruction
Audit may relate to the practice of ‘clinician reporting’
with stipulated levels of grading here, compared with
the potential inﬂuence of ‘patient recall’ after 3 months
in the national audit3. Furthermore, the potential for
chemotherapy to impair key domains in HRQL may
pertain not only to the early postoperative phase, but
may persist for 12 months or longer, emphasizing the
importance of integration into analyses of PROMs4,11.
Patients at diagnosis of breast cancer have impairedHRQL
compared with an age-matched population of women
without cancer, underscoring the importance of evaluating
preoperative or baseline HRQL when considering the
long-term effects of breast reconstruction on most HRQL
domains12,18.
Both systematic reviews of PROMs in breast reconstruc-
tion revealed a dearth of validated breast reconstruction-
speciﬁc questionnaires4,11. A phase 3 BREAST-Q ques-
tionnaire for breast reconstruction was published in 2009,
and validation of a European equivalent is in progress28,29.
The ﬁndings of similar effects on aspects of HRQL by type
of surgery in this cohort will require further study using
breast reconstruction-speciﬁc questionnaires.
Under-reporting of complications is common, despite
internationally agreedmethods for classiﬁcation4,11,23.The
UK breast reconstruction audit reported a higher than
expected number of level 2 (moderate) and level 3 (major)
complications (16 per cent) after similar types of breast
reconstruction3,23. Indeed, up to 52 per cent of women
experienced poor pain control at 3 months after breast
reconstruction, compared with relatively high levels of
postoperative pain (12 per cent) at 18 months3. In the
present study, the frequency of patients with level 3
complications requiring chronic treatment or reoperation
was 38·1 per cent up to 3 months after surgery, and
39 per cent from 4 to 12 months, among those with
complications23. This type of information should be
included in standardized informed consent procedures in
the future.
The prospective longitudinal cohort design helps guide
decision-making on breast reconstruction for patients and
surgeons. Informed consent for breast reconstruction must
include the effects of adjuvant treatments, with particular
attention to such issues in younger women for whom
reported preoperative HRQL scores are lower and anxiety
levels correspondingly higher. The majority of studies
report 12-month data only, and more prolonged follow-up
to 24 and 36 months is an important intended goal of this
study4,11. Clear and non-biased communication of existing
clinical evidence supported by PROMs is essential3,4,11.
This is the basis of standard information used in the
QUEST trial (the ﬁrst multicentre randomized trial of
breast reconstruction within the UK)30. Such attempts
represent a new era in the ﬁeld of breast reconstructive
practice where there is a pressing need for evidence-based
clinical decision-making in partnership with validated
PROMs.
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Snapshot Quiz
Answer
Snapshot Quiz 13/23
At laparotomy a torted and infarcted gallbladder was found, and a cholecystectomy was therefore performed.
The patient made an uneventful recovery. The authors advise that torsion of the gallbladder should be
considered in any individual with sudden-onset upper abdominal pain and no signs of toxaemia.
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